Having trouble viewing this email? View in your browser.
ESCMID Logo

30 January 2018
WEEKLY NEWS

Dear colleagues,

Young Scientist Members can apply here for the Mayo Clinic observership until 31 January (tomorrow)!

A paper on a survey ESGAP and ESGBIS conducted together was published in the International Journal of Antimicrobial Agents.

DRIVE-AB issued a final report on its research-based suggestions for driving antibiotic development while ensuring access and sustainable use.

While you are getting ready for Madrid, check out if you can spot yourself or your colleagues in the photo gallery for ECCMID 2017 in Vienna.

Your ESCMID communications editors

 

About 3,500 abstracts approved for presentation at ECCMID

Of the 5,315 abstracts submitted for ECCMID in Madrid, 755 were approved for oral presentation and 2,820 for poster presentation. Over 1,700 were rejected, which corresponds to a rejection rate of 32%. We congratulate all the successful submitters and are looking forward to their presentations at ECCMID from 21 – 24 April 2018.

From 15 February to 1 March 2018 we will accept the submission of late-breaking abstracts for the topics: clinical trials, vaccine-preventable diseases and others. Please look at the abstract guidelines for more information.

› Read more
 

Winners of 2018 TAE Awards for Training Achievements announced

Robbert Bentvelsen (pictured right), is a resident in clinical microbiology at Leiden University Centre, the Netherlands. He is a trained physician and as a resident he volunteered to lead the Dutch lab-team in Freetown, Sierra Leone, to help fight the Ebola outbreak. He has won the national prize of the Dutch Hacking Health competition with an infection prevention smartphone app in 2016. Robbert contributes to educate medical students and residents (geriatrics) in the Netherlands and helped in a training programme in Sierra Leone. Currently he is principal investigator in the Participatient project, which aims to reduce urinary tract infections via patient participation through a smartphone app.

Maroun Sfeir (pictured left) is highly involved in teaching medical students and residents at Weill Cornell Medicine during their rotations in the division of infectious disease. He has served as major educator of the microbiology course each autumn for medical students at Cornell University and has received many excellent feedbacks. He was awarded several honours and awards including the ID Week 2016 Trainee Award Grant for Outstanding Case Report. Given his multilingual proficiency, he was granted the Committee of Interns and Residents (CIR) Policy and Education Initiative Scholarship to provide volunteer medical relief in Haiti in 2015 where he spent the summer in Port-au-Prince local hospitals serving the Haitian population and leading workshops for the Haitian physicians.

The awardees will receive their awards during the TAE Day session on Saturday 21 April at ECCMID. 

› Read more
 

CMI highlight: E. coli bloodstream infection treatment and outcomes

Researchers from Bologna, Italy investigated the impact of treatment duration on mortality and on relapse in patients with bloodstream infection (BSI) caused by Escherichia coli. Of 856 patients analyzed 426 received short (≤ 10 days) and 430 received long (>10 days) therapy. All-cause mortality at day 90 occurred in 47 patients; at multivariate analysis, short therapy was not associated with higher risk of mortality also after adjusting the model for the propensity score of receiving short therapy. Relapse occurred in 42 patients. Independent risk factors for relapse using death as competing risk were immunosuppression, and end-stage-liver-disease. The propensity-weighted estimation of the average treatment effect for relapse reduction with long therapy was - 1.6% in the total population, and - 7.1% in immunocompromised patients. The researchers concluded that they could not identify shorter treatment duration as a risk factor for mortality and for relapse in patients with E. coli BSI.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.